Remedium Bio has secured $10 million in Series A funding to advance subcutaneous gene therapies designed to produce therapeutic proteins from fat tissue for multi-year duration with adjustable dosing. The platform targets replacement of repeated protein injections with single-administration gene therapy for cardiometabolic and chronic disease applications.
Key Points
- Adipocyte-based platform enables durable therapeutic protein production post-injection
- Single injection designed to replace multiple subcutaneous protein administrations
- Funding supports first-in-human trials and cardiometabolic disease development
Longevity Analysis
Gene therapy platforms that shift from frequent external administration to sustained internal production represent a fundamental change in how chronic disease management can be sustained over time. By leveraging the body's own cellular machinery to manufacture therapeutic proteins, this approach reduces the compliance burden that often undermines long-term treatment adherence. The adjustable dosing mechanism addresses a critical gap in current therapies: the inability to optimize protein levels based on individual response without repeated interventions. For conditions requiring sustained protein replacement—particularly those affecting metabolic regulation and cardiovascular function—reducing treatment friction while improving precision dosing could extend both lifespan and quality of life in populations currently dependent on complex medication regimens.
Original published by LT Wire.